Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
HBT-708 · 1 trial · 1 indication
Adverse event were defined as the appearance of undesirable signs, symptoms, or medical conditions that occurred after informed consent.
Adverse events were defined as the appearance of undesirable signs, symptoms, or medical conditions that occurred after a participant provided informed consent.
| Arm | Type | Description |
|---|---|---|
| Arm 1 | EXPERIMENTAL | Dose escalation will be conducted using an accelerated titration plus traditional 3+3 design. Dose Escalation includes 7 levels, Q3W IV. Dose extension will be carried out at the selected level. dose level 1 of HBT-708 Q3W i.v. |
| Arm 2 | EXPERIMENTAL | Dose escalation will be conducted using an accelerated titration plus traditional 3+3 design. Dose Escalation includes 7 levels, Q3W IV. Dose extension will be carried out at the selected level. dose level 2 of HBT-708 Q3W i.v. |
| Arm 3 | EXPERIMENTAL | Dose escalation will be conducted using an accelerated titration plus traditional 3+3 design. Dose Escalation includes 7 levels, Q3W IV. Dose extension will be carried out at the selected level. dose level 3 of HBT-708 Q3W i.v. |
| Arm 4 | EXPERIMENTAL | Dose escalation will be conducted using an accelerated titration plus traditional 3+3 design. Dose Escalation includes 7 levels, Q3W IV. Dose extension will be carried out at the selected level. dose level 4 of HBT-708 Q3W i.v. |
| Arm 5 | EXPERIMENTAL | Dose escalation will be conducted using an accelerated titration plus traditional 3+3 design. Dose Escalation includes 7 levels, Q3W IV. Dose extension will be carried out at the selected level. dose level 5 of HBT-708 Q3W i.v. |
| Arm 6 | EXPERIMENTAL | Dose escalation will be conducted using an accelerated titration plus traditional 3+3 design. Dose Escalation includes 7 levels, Q3W IV. Dose extension will be carried out at the selected level. dose level 6 of HBT-708 Q3W i.v. |
| Arm 7 | EXPERIMENTAL | Dose escalation will be conducted using an accelerated titration plus traditional 3+3 design. Dose Escalation includes 7 levels, Q3W IV. Dose extension will be carried out at the selected level. dose level 7 of HBT-708 Q3W i.v. |
| Name | Type | Description |
|---|---|---|
| HBT-708 | DRUG | bispecific antibody |
Inclusion Criteria: 1. Male or female subjects, age 18 years or older. 2. Histologically and/or cytologically documented advanced or measurable solid tumors. 3. Eastern Cooperative Oncology Group (ECOG) performance status of 0-1. 4. Life expectancey \> = 3 months. 5. Willingness to provide written ...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| Merck & Co., Inc. | MRK | 2 | PHASE2 | pembrolizumab |
| Incyte Corporation | INCY | 1 | PHASE2 | Chemotherapy, Retifanlimab |
| Iovance Biotherapeutics Inc | IOVA | 2 | PHASE2 | E7 TCR-T cells, Aldesleukin |
| Novartis AG Sponsored ADR | NVS | 1 | PHASE1 | KFA115, pembrolizumab |
| AstraZeneca PLC | AZN | 1 | - | Trastuzumab deruxtecan |
HBT-708 is an investigational small molecule being developed for the treatment of advanced solid tumors. It is currently in Phase 1 clinical development, with an ongoing study evaluating its safety and efficacy in patients with advanced solid tumors.
HBT-708 is a small molecule designed to target cancer cells in advanced solid tumors. Its specific molecular target has not been disclosed, but it is being studied for its potential to treat patients with advanced solid tumors.
HBT-708 is being developed by Sunshine Biopharma Inc., a biopharmaceutical company listed on the stock exchange under the ticker symbol SBFM. The company is conducting clinical trials to evaluate the drug's safety and efficacy.
HBT-708 is currently in Phase 1 clinical development. It is an investigational drug and has not yet been approved by regulatory authorities. The ongoing Phase 1 trial is recruiting patients with advanced solid tumors.
HBT-708 is being studied in a Phase 1 clinical trial with the identifier NCT06993870. This trial is recruiting patients with advanced solid tumors and is being conducted in China. The study aims to enroll approximately 60 participants.
HBT-708 is a unique investigational drug candidate developed by Sunshine Biopharma Inc. There are no alternative names or known aliases for this drug at this time.